Trump administration secures deals to lower obesity drug prices

cnbc.com

President Trump announced deals with Eli Lilly and Novo Nordisk to significantly lower prices for obesity drugs, expanding access for Medicare and Medicaid beneficiaries. The agreements, effective in 2026, will cap starting doses of new obesity pills at $145 monthly and existing injections at $350, with Medicare covering these treatments for eligible patients for the first time. These deals are part of the administration's broader initiative to reduce U.S. drug costs by linking them to international prices, aiming to make these costly blockbuster treatments more affordable.


With a significance score of 6.2, this news ranks in the top 0.2% of today's 33244 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: